Radioguided Selective Neck Dissection for Staging and Treatment of Oral Cavity and Oropharyngeal Squamous Cell Carcinoma
- Conditions
- Oropharyngeal Squamous Cell CarcinomaOral Cavity Squamous Cell Carcinoma
- Registration Number
- NCT03727594
- Lead Sponsor
- University Hospital of Ferrara
- Brief Summary
The purpose of the study is to assess the role of lymphoscintigraphy as a simple and widely accessible method with a favorable cost/benefit ratio in improving oral cavity and oropharyngeal squamous cell carcinoma staging and surgical appropriateness and implementing a tailored surgical approach to cervical lymph node dissection.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 50
- accepted informed consent
- preoperative histological diagnosis of oral cavity or oropharyngeal squamous cell carcinoma
- patients fit to surgery of the primitive tumor and neck dissection (according to the general health condition and the clinical tumor stage)
- rejected informed consent
- patients not fit to surgery (according to the general health condition and the clinical tumor stage)
- pregnant women
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival 5 years Prognosis of radioguided neck dissection surgery compared to the standardized neck dissection traditionally performed in consideration of the site and the characteristics of the tumor and the clinical status of lymphnodes.
Number of patients with atypical lymphatic drainage of oral cavity and oropharyngeal squamous cell carcinoma identified through lymphoscintigraphy 5 years Number of metastasis or micrometastasis in the "sentinel" lymphnodes identified through immunofluorescence analysis of pancytokeratins 5 years Disease-free survival 5 years Prognosis of radioguided neck dissection surgery compared to the standardized neck dissection traditionally performed in consideration of the site and the characteristics of the tumor and the clinical status of lymphnodes.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University Hospital of Ferrara
🇮🇹Ferrara, Italy